Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide

Husam Albarmawi; Firas Dabbous; Abdalla Aly; Alia Yousif; Samuel Huse; Maximilian Jara; Andres Quintero; Eric Lawitz

doi:10.1080/03007995.2025.2596430

Abstract

In patients with MASH and either overweight or obesity, semaglutide was associated with a clinically and statistically significant reduction in ALT after 6 months of continuous use. Reductions in AST, weight, and HbA1c were also observed.

Affiliated Institutions

Related Publications

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding , Rachel L. Batterham , Salvatore Calanna +11 more

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body we...

2021 New England Journal of Medicine 3574 citations

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

Brent A. Neuschwander‐Tetri

Insulin resistance (IR) commonly is associated with nonalcoholic steatohepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving...

2003 Hepatology 699 citations

Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome

Giulio Marchesini , Elisabetta Bugianesi , Gabriele Forlani +8 more

Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin–resistance syndrome, at present defined as the metabolic syndrome, whose limits were recently set. ...

2003 Hepatology 2654 citations

Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study

Clara Depommier , Amandine Everard , Céline Druart +13 more

Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type...

2019 Nature Medicine 2008 citations

The future of obesity reduction: beyond weight loss

Robert Ross , Alison Bradshaw

Obesity increases the risk of morbidity and mortality and reduces quality of life independent of age, sex or ethnicity. Leading health authorities recommend weight loss as a pri...

2009 Nature Reviews Endocrinology 242 citations

Publication Info

Year: 2025
Type: article
Pages: 1-14
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Husam Albarmawi, 
                                
                                    Firas Dabbous, 
                                
                                    Abdalla Aly
                                
                                et al.
                            
                            (2025). 
                            Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide. 
                            Current Medical Research and Opinion
                            
                            , 1-14.
                            https://doi.org/10.1080/03007995.2025.2596430

Identifiers

DOI: 10.1080/03007995.2025.2596430